National Cancer Institute Awards $1 Million in SBIR Funding to BioMarker Strategies

BALTIMORE--(BUSINESS WIRE)--BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company’s Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients. Under this contract, the company is eligible to receive an additional $1 million in April of 2011, for a total potential contract award of $2.3 million.